1:05 PM
 | 
Apr 12, 2018
 |  BC Extra  |  Financial News

Pain company Sollis raises $50M

Sollis Therapeutics (Columbus, Ohio) raised $50 million in a series A round led by Deerfield. Sollis declined to disclose details.

Sollis' lead product, STX-015, is an extended-release combination of an analgesic and anti-inflammatory medication to treat sciatica and other neuropathic pain syndromes. President and CEO Gregory Fiore told BioCentury that Sollis expects to enroll patients in a Phase III trial of the therapy in the next six to nine months.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD